MDC-CAR-BCMA001 (BCMA directed CAR T-cells)

Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy

The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies

Live record on ClinicalTrials.gov →

• Male or female patients aged ≥ 18 years
• Written informed consent of the subject
• Able and willing to adhere to the trial protocol
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Either Multiple Myeloma (MM):
• relapsed or refractory disease after at least 2 lines of treatment including an Immunomodulatory drug, a proteasome inhibitor and an anti-cluster of differentiation 38 antibody or anti-cluster of differentiation 319 (SLAMF7; Elotuzumab) antibody AND

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.